Ali M. Abdelaziz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali M. Abdelaziz has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Muhammed Elhadi
College of Medicine, Korea University, Seoul, South Korea
6 shared publications - Pierre Sabouret
ACTION Study Group, Inserm UMRS1166, Heart Institute, Pitié-Salpetriere Hospital, Sorbonne University, 75013 Paris, France
4 shared publications Mohamedhen Vall Nounou
3 shared publications- Giuseppe Andò
Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy
2 shared publications - Luigi Spadafora
Division of Cardiology and Interventional Cardiology, Santa Maria Goretti Hospital, Latina, Italy
2 shared publications - Mamas Andreas Mamas
Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Carotid Plaque Score: A Useful Tool or Futile Gadget for Risk Assessment? An Update
Conventional cardiovascular risk scores estimate the probability of future events; however, these risk scores do not directly quantify the presence or extent of subclinical atherosclerosis. This narrative review critically evaluates the current evidence on the carotid plaque score (CPS), a semiquantitative ultrasound-based measure of carotid atherosclerotic burden across predefined arterial segments. Population-based cohorts have consistently shown that carotid plaque presence and burden are independently associated with cardiovascular and cerebrovascular events. Studies specifically evaluating CPS have further suggested an incremental prognostic value beyond conventional risk models, particularly for ischemic stroke and major adverse cardiovascular event (MACE). However, CPS does not represent a single standardized metric. Therefore, proposed thresholds, including CPS ≥2 and CPS >3, were derived using different plaque definitions, arterial segments, scoring methods, and study populations and are not directly interchangeable. Meanwhile, CPS is more accessible, non-ionizing, and relatively inexpensive compared with coronary artery calcium (CAC), but it is less extensively validated and less standardized. Nonetheless, available comparative evidence indicates that CAC provides superior discrimination for coronary outcomes. In contrast, carotid plaque assessment may offer complementary information for cerebrovascular risk and in selected individuals with discordant estimated risk or no detectable coronary calcification. No randomized trial has demonstrated that treatment decisions guided by CPS improve clinical outcomes. Accordingly, current guidelines generally position carotid plaque imaging as a selective risk modifier rather than a routine screening or stand-alone treatment-allocation tool. Thus, broader clinical implementation will require standardized acquisition and reporting protocols, external validation across diverse populations, integration with established risk models, and prospective studies evaluating whether CPS-guided preventive strategies improve patient outcomes.
- 23 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Open AccessCarotid Plaque Score: A Useful Tool or Futile Gadget for Risk Assessment? An Update
Conventional cardiovascular risk scores estimate the probability of future events; however, these risk scores do not directly quantify the presence or extent of subclinical atherosclerosis. This narrative review critically evaluates the current evidence on the carotid plaque score (CPS), a semiquantitative ultrasound-based measure of carotid atherosclerotic burden across predefined arterial segments. Population-based cohorts have consistently shown that carotid plaque presence and burden are independently associated with cardiovascular and cerebrovascular events. Studies specifically evaluating CPS have further suggested an incremental prognostic value beyond conventional risk models, particularly for ischemic stroke and major adverse cardiovascular event (MACE). However, CPS does not represent a single standardized metric. Therefore, proposed thresholds, including CPS ≥2 and CPS >3, were derived using different plaque definitions, arterial segments, scoring methods, and study populations and are not directly interchangeable. Meanwhile, CPS is more accessible, non-ionizing, and relatively inexpensive compared with coronary artery calcium (CAC), but it is less extensively validated and less standardized. Nonetheless, available comparative evidence indicates that CAC provides superior discrimination for coronary outcomes. In contrast, carotid plaque assessment may offer complementary information for cerebrovascular risk and in selected individuals with discordant estimated risk or no detectable coronary calcification. No randomized trial has demonstrated that treatment decisions guided by CPS improve clinical outcomes. Accordingly, current guidelines generally position carotid plaque imaging as a selective risk modifier rather than a routine screening or stand-alone treatment-allocation tool. Thus, broader clinical implementation will require standardized acquisition and reporting protocols, external validation across diverse populations, integration with established risk models, and prospective studies evaluating whether CPS-guided preventive strategies improve patient outcomes.
- Open Access
- 18 September 2026
- Published by Elsevier in American Journal of Preventive Cardiology
Residual cardiovascular risk in patients with established atherosclerotic cardiovascular disease achieving LDL-C <55 mg/dL
- 18 September 2026
- Published by Elsevier in American Journal of Preventive Cardiology
Open AccessResidual cardiovascular risk in patients with established atherosclerotic cardiovascular disease achieving LDL-C <55 mg/dL
- Open Access
- 24 July 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (9)
Sex-Specific Differences in Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Reconstructed Individual Patient Survival Data
- 24 July 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (9)
Open AccessSex-Specific Differences in Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Reconstructed Individual Patient Survival Data
- Open Access
- 18 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2325
Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies
Arterial thrombosis emerges from the interplay between plaque disruption, platelet activation, and coagulation pathway amplification on a background of heterogeneous ischemic and bleeding risk. Optimal antithrombotic therapy therefore varies across clinical settings, from acute coronary syndromes (ACS) to chronic coronary syndromes (CCS), ischemic stroke, peripheral artery disease (PAD), and atrial fibrillation (AF) associated with atherosclerotic disease. Contemporary European and North American guidelines endorse an increasingly individualized approach, moving away from rigid “one-size-fits-all” dual antiplatelet therapy (DAPT) duration and intensity and incorporating dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk CCS and PAD patients. In ischemic stroke, short-course DAPT is confined to minor events and transient ischemic attacks, whereas long-term monotherapy remains standard, and the coexistence of AF typically shifts the balance toward oral anticoagulation. Across all scenarios, antithrombotic benefit must be weighed against bleeding, especially in elderly, frail, or comorbid patients. Evidence gaps remain substantial, particularly in patients with overlapping vascular territories, AF plus atherosclerotic disease, and after ischemic stroke of complex or mixed mechanisms. This narrative review summarizes current evidence and guideline-based strategies in major atherosclerotic settings, proposes a unifying conceptual framework, and highlights key uncertainties and research directions for truly personalized antithrombotic care.
- 18 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2325
Open AccessOptimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies
Arterial thrombosis emerges from the interplay between plaque disruption, platelet activation, and coagulation pathway amplification on a background of heterogeneous ischemic and bleeding risk. Optimal antithrombotic therapy therefore varies across clinical settings, from acute coronary syndromes (ACS) to chronic coronary syndromes (CCS), ischemic stroke, peripheral artery disease (PAD), and atrial fibrillation (AF) associated with atherosclerotic disease. Contemporary European and North American guidelines endorse an increasingly individualized approach, moving away from rigid “one-size-fits-all” dual antiplatelet therapy (DAPT) duration and intensity and incorporating dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk CCS and PAD patients. In ischemic stroke, short-course DAPT is confined to minor events and transient ischemic attacks, whereas long-term monotherapy remains standard, and the coexistence of AF typically shifts the balance toward oral anticoagulation. Across all scenarios, antithrombotic benefit must be weighed against bleeding, especially in elderly, frail, or comorbid patients. Evidence gaps remain substantial, particularly in patients with overlapping vascular territories, AF plus atherosclerotic disease, and after ischemic stroke of complex or mixed mechanisms. This narrative review summarizes current evidence and guideline-based strategies in major atherosclerotic settings, proposes a unifying conceptual framework, and highlights key uncertainties and research directions for truly personalized antithrombotic care.
- Open Access
- 23 January 2026
- Published by S. Karger AG in Cardiology
- p. 1-13
Sex Disparities in Mortality and Clinical Characteristics in Patients with Infective Endocarditis: A Meta-Analysis of Reconstructed Time-to-Event Data
Introduction: Sex disparities in the clinical presentation, management, and outcomes of infective endocarditis (IE) remain inconsistent throughout the literature. We aimed to investigate the prognostic impact of sex-associated disparities in all-cause mortality and baseline clinical characteristics among patients with IE. Methods: We comprehensively searched PubMed, Scopus, Embase, and Web of Science till July 2025 for studies reporting sex-specific data on clinical presentation, mortality, and management patterns in IE. We reconstructed individual patient data from published Kaplan-Meier plots for all-cause mortality and estimated HR with 95% CI using a Cox regression model. Data regarding clinical presentation, microbiological profile, and management were pooled using random-effects meta-analysis. Results: Eighteen studies comprising 12,594 female and 24,365 male patients were included. Female sex was associated with a higher risk of mortality (HR: 1.338, 95% CI: 1.272–1.407, p < 0.001). Women more often had mitral valve endocarditis and valve vegetations but less frequently aortic valve endocarditis and intracardiac abscesses. Rates of surgical indication were similar between sexes, yet women underwent surgery less often, coinciding with higher baseline EuroScore II. Enterococcal infections were less common in women, with no significant sex differences for other microbiological etiologies. Conclusion: Women with IE experience higher mortality than men despite similar surgical indications, alongside distinctive valve involvement patterns, higher baseline surgical risk, and lower surgical intervention rates. Earlier recognition, timely intervention, and optimized surgical decision-making in women may help reduce this disparity.
- 23 January 2026
- Published by S. Karger AG in Cardiology
- p. 1-13
Open AccessSex Disparities in Mortality and Clinical Characteristics in Patients with Infective Endocarditis: A Meta-Analysis of Reconstructed Time-to-Event Data
Introduction: Sex disparities in the clinical presentation, management, and outcomes of infective endocarditis (IE) remain inconsistent throughout the literature. We aimed to investigate the prognostic impact of sex-associated disparities in all-cause mortality and baseline clinical characteristics among patients with IE. Methods: We comprehensively searched PubMed, Scopus, Embase, and Web of Science till July 2025 for studies reporting sex-specific data on clinical presentation, mortality, and management patterns in IE. We reconstructed individual patient data from published Kaplan-Meier plots for all-cause mortality and estimated HR with 95% CI using a Cox regression model. Data regarding clinical presentation, microbiological profile, and management were pooled using random-effects meta-analysis. Results: Eighteen studies comprising 12,594 female and 24,365 male patients were included. Female sex was associated with a higher risk of mortality (HR: 1.338, 95% CI: 1.272–1.407, p < 0.001). Women more often had mitral valve endocarditis and valve vegetations but less frequently aortic valve endocarditis and intracardiac abscesses. Rates of surgical indication were similar between sexes, yet women underwent surgery less often, coinciding with higher baseline EuroScore II. Enterococcal infections were less common in women, with no significant sex differences for other microbiological etiologies. Conclusion: Women with IE experience higher mortality than men despite similar surgical indications, alongside distinctive valve involvement patterns, higher baseline surgical risk, and lower surgical intervention rates. Earlier recognition, timely intervention, and optimized surgical decision-making in women may help reduce this disparity.
- Open Access
- 23 October 2025
- Published by S. Karger AG in Cardiology
- p. 1-9
Efficacy and Safety of Protamine Use following Transcatheter Aortic Valve Implantation for Minimizing Post-Procedural Bleeding Risk: A Systematic Review and Meta-Analysis
Introduction: Transcatheter aortic valve implantation (TAVI) may be complicated by postoperative bleeding due to heparin use. Heparin antagonists, such as protamine, have shown potential in reducing bleeding risks. This meta-analysis assesses the efficacy and safety of protamine in reducing bleeding complications after TAVI. Methods: A systematic search was conducted up to March 2025. Inclusion criteria encompassed studies reporting the use of protamine post-TAVI with a control group. Primary outcomes included major bleeding events as the efficacy endpoint, 30-day mortality, and ischemic events (stroke and transient ischemic attack, or TIA) as safety endpoints. Secondary outcomes included life-threatening bleeding events and the need for blood transfusion. A random-effects model was used to calculate odds ratios (ORs). Results: Four studies involving 1,569 patients were included. As compared to the control group, protamine was not associated with a statistically significant difference in major bleeding events (OR = 0.59, 95% CI = 0.26–1.34, p = 0.21), life-threatening bleeding events (OR = 0.3, 95% CI = 0.06–1.62, p = 0.16), need for blood transfusions (OR = 0.75, 95% CI = 0.46–1.24, p = 0.27), 30-day mortality (OR = 1.07, 95% CI = 0.54–2.11, p = 0.85), or rate of stroke and TIA (OR = 0.86, 95% CI = 0.05–13.58, p = 0.91). Conclusion: Protamine use after TAVI appeared to be safe with no increase in 30-day mortality or stroke and TIA rates, but there was no observed statistically significant benefit in the reduction of major or life-threatening bleeding events and the need for blood transfusions. These findings are based on a limited number of studies, and larger randomized controlled trials are warranted to confirm them.
- 23 October 2025
- Published by S. Karger AG in Cardiology
- p. 1-9
Open AccessEfficacy and Safety of Protamine Use following Transcatheter Aortic Valve Implantation for Minimizing Post-Procedural Bleeding Risk: A Systematic Review and Meta-Analysis
Introduction: Transcatheter aortic valve implantation (TAVI) may be complicated by postoperative bleeding due to heparin use. Heparin antagonists, such as protamine, have shown potential in reducing bleeding risks. This meta-analysis assesses the efficacy and safety of protamine in reducing bleeding complications after TAVI. Methods: A systematic search was conducted up to March 2025. Inclusion criteria encompassed studies reporting the use of protamine post-TAVI with a control group. Primary outcomes included major bleeding events as the efficacy endpoint, 30-day mortality, and ischemic events (stroke and transient ischemic attack, or TIA) as safety endpoints. Secondary outcomes included life-threatening bleeding events and the need for blood transfusion. A random-effects model was used to calculate odds ratios (ORs). Results: Four studies involving 1,569 patients were included. As compared to the control group, protamine was not associated with a statistically significant difference in major bleeding events (OR = 0.59, 95% CI = 0.26–1.34, p = 0.21), life-threatening bleeding events (OR = 0.3, 95% CI = 0.06–1.62, p = 0.16), need for blood transfusions (OR = 0.75, 95% CI = 0.46–1.24, p = 0.27), 30-day mortality (OR = 1.07, 95% CI = 0.54–2.11, p = 0.85), or rate of stroke and TIA (OR = 0.86, 95% CI = 0.05–13.58, p = 0.91). Conclusion: Protamine use after TAVI appeared to be safe with no increase in 30-day mortality or stroke and TIA rates, but there was no observed statistically significant benefit in the reduction of major or life-threatening bleeding events and the need for blood transfusions. These findings are based on a limited number of studies, and larger randomized controlled trials are warranted to confirm them.
- 20 February 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (6) , 1311-1319
Comparative Efficacy and Safety of Low‐Dose Direct Oral Anticoagulants Versus Dual Antiplatelet Therapy Following Left Atrial Appendage Occlusion in Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta‐Analysis
Background: Left atrial appendage occlusion (LAAO) is an alternative to chronic oral anticoagulation (OAT) for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients with contraindications to OAT. Postprocedure antithrombotic therapy (ATT) is essential to reduce the risk of device‐related thrombosis (DRT), but the optimal regimen remains uncertain.Aims: This study aims to compare the safety and efficacy of low‐dose direct oral anticoagulants (DOACs) versus dual antiplatelet therapy (DAPT) following LAAO.Methods: A comprehensive search of PubMed, Scopus, Cochrane, and Web of Science was conducted in August 2024. Studies comparing low‐dose DOACs and DAPT post‐LAAO were included. The primary outcomes were a composite efficacy endpoint (DRT, strokes, and systemic embolism [SE]) and major bleeding events as the safety endpoint. Secondary outcomes included all bleeding events, all‐cause mortality, and a composite of efficacy and safety endpoints.Results: Four studies with 727 patients were included. Low‐dose DOACs were associated with lower rates of the primary composite efficacy endpoint compared to DAPT (OR = 0.36; 95% CI [0.16, 0.85], p = 0.01). No significant difference in major bleeding events was observed (OR = 0.36; 95% CI [0.11, 1.18]; p = 0.091; I² = 0%). Compared to DAPT, low‐dose DOACs were also associated with lower rates of DRT events (OR = 0.36; 95% CI [0.16, 0.79], p = 0.011).Conclusion: Low‐dose DOACs effectively reduce thromboembolic events post‐LAAO without increasing bleeding risk. These findings support their use as a viable ATT option, but larger trials are needed to confirm optimal regimens.
- 20 February 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (6) , 1311-1319
Comparative Efficacy and Safety of Low‐Dose Direct Oral Anticoagulants Versus Dual Antiplatelet Therapy Following Left Atrial Appendage Occlusion in Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta‐Analysis
Background: Left atrial appendage occlusion (LAAO) is an alternative to chronic oral anticoagulation (OAT) for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients with contraindications to OAT. Postprocedure antithrombotic therapy (ATT) is essential to reduce the risk of device‐related thrombosis (DRT), but the optimal regimen remains uncertain.Aims: This study aims to compare the safety and efficacy of low‐dose direct oral anticoagulants (DOACs) versus dual antiplatelet therapy (DAPT) following LAAO.Methods: A comprehensive search of PubMed, Scopus, Cochrane, and Web of Science was conducted in August 2024. Studies comparing low‐dose DOACs and DAPT post‐LAAO were included. The primary outcomes were a composite efficacy endpoint (DRT, strokes, and systemic embolism [SE]) and major bleeding events as the safety endpoint. Secondary outcomes included all bleeding events, all‐cause mortality, and a composite of efficacy and safety endpoints.Results: Four studies with 727 patients were included. Low‐dose DOACs were associated with lower rates of the primary composite efficacy endpoint compared to DAPT (OR = 0.36; 95% CI [0.16, 0.85], p = 0.01). No significant difference in major bleeding events was observed (OR = 0.36; 95% CI [0.11, 1.18]; p = 0.091; I² = 0%). Compared to DAPT, low‐dose DOACs were also associated with lower rates of DRT events (OR = 0.36; 95% CI [0.16, 0.79], p = 0.011).Conclusion: Low‐dose DOACs effectively reduce thromboembolic events post‐LAAO without increasing bleeding risk. These findings support their use as a viable ATT option, but larger trials are needed to confirm optimal regimens.
- Open Access
- 1 January 2025
- Published by XMLink in Clinical Hypertension
- Vol. 31 (1)
Efficacy and safety of selective aldosterone synthase inhibitors in uncontrolled hypertension: a systematic review and meta-analysis of randomized controlled trials
Louat A, et al. Clin Hypertens. 2025 Dec;31:e41. https://doi.org/10.5646/ch.2025.31.e41
- 1 January 2025
- Published by XMLink in Clinical Hypertension
- Vol. 31 (1)
Open AccessEfficacy and safety of selective aldosterone synthase inhibitors in uncontrolled hypertension: a systematic review and meta-analysis of randomized controlled trials
Louat A, et al. Clin Hypertens. 2025 Dec;31:e41. https://doi.org/10.5646/ch.2025.31.e41